https://www.selleckchem.com/pr....oducts/evobrutinib.h
4 (95% CI 5.2-7.6) for new users; the corresponding SIRs were 3.1 (95% CI 2.9-3.3) and 3.5 (95% CI 2.9-4.3). In the second and subsequent years, the SIRs diminished and approached unity for both prevalent (1.1 [95% CI 1.1-1.2]) and new users (1.1 [95% CI 0.9-1.3]). VTE patients using statins had a 3-fold increased rate of cancer in the first year after diagnosis. A first VTE serves as an important marker of cancer, regardless of statin use. VTE patients using statins had a 3-fold increased rate of cancer in the first year after diag
Like
Comment
Share
